Recently, the 2023 Jiangsu Top 100 Private Enterprises series list was released. JumpCan Pharmaceutical Group Co., Ltd. (hereinafter referred to as "JumpCan") was included in both the "2023 Jiangsu Top 100 Innovative Private Enterprises" list and the "2023 Jiangsu Socially Responsible Leading Private Enterprises" list, highlighting the company's efforts and achievements in innovation and social contribution.
"2023 Jiangsu Top 100 Innovative Private Enterprises" list and "2023 Jiangsu Socially Responsible Leading Private Enterprises" list
JumpCan has always adhered to its corporate mission of " Using Technology to Defend Health", keeping pace with national healthcare policies, evolving market conditions, technological advancements, and rising patient needs. During different phases of development, the company has proactively embraced change and pursued innovation, promoting high-quality growth in its three core industries—integrated Chinese and Western Pharmaceuticals, TCM personal care, and TCM health products—contributing to the Healthy China strategy while actively undertaking social responsibilities. Thanks to its strong resilience, the company has received a series of honors and recognitions, further enhancing its reputation and public trust.
Charitable and public welfare activities of JumpCan
In 2023, JumpCan continued to empower its industry through technology and drive development through innovation. By adopting innovative models, upgrading products, and optimizing management, the company has consistently improved its economic performance and core competitiveness. It has obtained multiple Drug Registration Certificates for products such as Sodium Valproate Concentrated Solution for Injection, Azithromycin for Suspension, Pregabalin Oral Solution, and Atomoxetine Hydrochloride Oral Solution. The company has also completed production applications for Sitafloxacin Granules, Macrogol Sodium Potassium Powder, and Sodium Valproate Sustained-Release Tablets, as well as a consistency evaluation application for Alanyl Glutamine Injection. Additionally, on-site registration inspections for Xiao'er Chiqiao Qingre Syrup and Lidocaine Carbonate Injection have been carried out, further strengthening the company's core competitiveness. In August of this year, JumpCan signed an exclusive strategic cooperation agreement with Zenshine Pharmaceuticals, securing exclusive promotion rights for an oral preparation of a polymerase acidic protein (PA) inhibitor used to treat or prevent influenza. This expands the company's commercial services into higher, broader, and newer domains, providing further momentum for high-quality development.
Multiple products obtained Drug Registration Certificates
Honors recognize the past and inspire the future. Taking this listing as an opportunity, JumpCan will further embody the spirit of Jiangsu private enterprises to "Set an Example, Demonstrate Excellence, and Lead the Way". Building on its competitive market advantages, the company will accelerate intelligent transformation and digitalization, enhance innovation in product R&D, business models, and management systems, and strengthen, supplement, and extend its industrial supply chain. Committed to become a leading, comprehensive pharmaceutical group trusted by patients, JumpCan will continue to write a new chapter of green, healthy, and sustainable high-quality development.
